NCT01344083

Brief Summary

The aim of this study is to compare the efficacy and the safety of T1210 versus Olopatadine eye drops in the topical treatment of seasonal allergic conjunctivitis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Apr 2011

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

April 21, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 28, 2011

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2012

Completed
Last Updated

April 12, 2012

Status Verified

April 1, 2011

Enrollment Period

10 months

First QC Date

April 21, 2011

Last Update Submit

April 11, 2012

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change from baseline of the score of tearing

    Day 28

  • Change from baseline of the score of itching

    Day 28

  • Change from baseline of the score of conjunctival hyperaemia

    Day 28

Secondary Outcomes (2)

  • Global local tolerance assessment by the Investigator and the patient

    Day 7

  • Global local tolerance assessment by the Investigator and the patient

    Day 28

Study Arms (2)

T1210

EXPERIMENTAL
Drug: T1210

Olopatadine hydrochloride

ACTIVE COMPARATOR
Drug: Olopatadine hydrochloride

Interventions

T1210DRUG

2 drops T1210 once a day

T1210

2 drops once a day Olopatadine

Olopatadine hydrochloride

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Written informed consent
  • Conjunctivitis allergic conjunctivitis

You may not qualify if:

  • Severe ocular allergy
  • Vernal keratoconjunctivitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pierre Huguet

Clermont-Ferrand, 63000, France

Location

MeSH Terms

Interventions

Olopatadine Hydrochloride

Intervention Hierarchy (Ancestors)

DibenzoxepinsHeterocyclic Compounds, 3-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2011

First Posted

April 28, 2011

Study Start

April 1, 2011

Primary Completion

February 1, 2012

Study Completion

February 1, 2012

Last Updated

April 12, 2012

Record last verified: 2011-04

Locations